Anne Fields - Opko Health IR Contact Officer
| OPK Stock | USD 1.30 0.03 2.36% |
Executive
Anne Fields is IR Contact Officer of Opko Health
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has Return on Asset of (0.0473) % which means that on every $100 spent on assets, it lost $0.0473. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.128) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.41. The value of Return On Capital Employed is expected to slide to -0.09. At this time, Opko Health's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to 0.00 this year, although the value of Total Current Liabilities will most likely fall to about 103.9 M.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| John JD | Adial Pharmaceuticals | N/A | |
| Karen Brunke | Jaguar Animal Health | 71 | |
| David JD | Pulmatrix | 66 | |
| Bankole Johnson | Adial Pharmaceuticals | 58 | |
| Brian Groch | Acasti Pharma | N/A | |
| James Roach | Pulmatrix | N/A | |
| David Hava | Pulmatrix | 40 | |
| Philippe Brianceau | Jaguar Animal Health | N/A | |
| Carol MBA | Jaguar Animal Health | 60 | |
| Roger Waltzman | Jaguar Animal Health | N/A | |
| Serge Martinod | Jaguar Animal Health | 57 | |
| Robert CPA | Acasti Pharma | 52 | |
| Peter Hodge | Jaguar Animal Health | N/A | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Dmitry Kolosov, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, President Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 1.12 B | ||||
| Shares Outstanding | 696.99 M | ||||
| Shares Owned By Insiders | 52.40 % | ||||
| Shares Owned By Institutions | 25.29 % | ||||
| Number Of Shares Shorted | 78.03 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Opko Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.25) | Revenue Per Share 1.149 | Quarterly Revenue Growth (0.02) | Return On Assets (0.05) |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.